Anneliese Schneider

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Journal: Clinical pharmacology and therapeutics

Published: March 07, 2026

Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs.

Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs.

Journal: mAbs

Published: November 06, 2025

Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates.

Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates.

Journal: Journal of immunotoxicology

Published: August 11, 2025

The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?

The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?

Journal: Expert opinion on drug discovery

Published: June 23, 2025

Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids.

Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids.

Journal: Nature biomedical engineering

Published: September 24, 2022

Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.

Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.

Journal: Oncoimmunology

Published: February 21, 2022

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.

Journal: Journal for immunotherapy of cancer

Published: December 11, 2021

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.

Journal: Journal for immunotherapy of cancer

Published: July 05, 2021

Human immunocompetent choroid-on-chip: a novel tool for studying ocular effects of biological drugs.

Human immunocompetent choroid-on-chip: a novel tool for studying ocular effects of biological drugs.

Journal: Communications biology

Published: May 26, 2021

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.

Journal: eLife

Published: January 31, 2021

Inducing anti-tumor cytokines and an immune response in melanoma by inhibition of MIA using the peptide AR71.

Inducing anti-tumor cytokines and an immune response in melanoma by inhibition of MIA using the peptide AR71.

Journal: European journal of dermatology : EJD

Published: January 14, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026